|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
36
|
|
pubmed:dateCreated |
2008-12-19
|
|
pubmed:abstractText |
Patients with myelodysplastic syndromes (MDS) often require treatment with growth factors (GFs) or non-GF therapies. One non-GF drug, lenalidomide, is particularly effective at achieving transfusion independence (TI) in patients with lower-risk MDS with the del(5q) cytogenetic abnormality. However, approximately half of del(5q) patients and one quarter of non-del(5q) patients treated with lenalidomide experience significant cytopenias. Lenalidomide-induced cytopenias occurring early in treatment may serve as a surrogate marker of clonal suppression and, therefore, may be predictive of a TI response.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-10229238,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-10577986,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-10643532,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-11418482,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-11493439,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-11535540,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-12011120,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-12239137,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-16532500,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-16609072,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-16651646,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-16651647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-16687173,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-16882708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-16921040,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-17021321,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-17258073,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-17345612,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-17391492,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-17893227,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-8861747,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19018091-9058730
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5943-9
|
|
pubmed:dateRevised |
2010-9-22
|
|
pubmed:meshHeading |
pubmed-meshheading:19018091-Adult,
pubmed-meshheading:19018091-Aged,
pubmed-meshheading:19018091-Aged, 80 and over,
pubmed-meshheading:19018091-Antineoplastic Agents,
pubmed-meshheading:19018091-Erythrocyte Transfusion,
pubmed-meshheading:19018091-Female,
pubmed-meshheading:19018091-Humans,
pubmed-meshheading:19018091-Male,
pubmed-meshheading:19018091-Middle Aged,
pubmed-meshheading:19018091-Myelodysplastic Syndromes,
pubmed-meshheading:19018091-Neutropenia,
pubmed-meshheading:19018091-Thalidomide,
pubmed-meshheading:19018091-Thrombocytopenia
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
|
|
pubmed:affiliation |
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Desk R35, 9500 Euclid Ave, Cleveland, OH 44195, USA. sekerem@ccf.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
